BioCryst to buy Astria Therapeutics in $700 million deal

Astria Therapeutics

14/10/2025 12:16

Oct 14 (Reuters) - BioCryst Pharmaceuticals BCRX.O said on Tuesday it would buy Astria Therapeutics ATXS.O in a cash-and-stock deal valued at about $700 million, as it looks to expand its portfolio of treatments for rare diseases.

 (Reporting by Siddhi Mahatole in Bengaluru; Editing by Shilpi Majumdar)

 ((siddhi.mahatole@thomsonreuters.com;))